- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07946614
Heparin Versus Saline Locking of Peripheral Venous Catheters (HESAL)
Heparin Versus Saline Locking of Peripheral Venous Catheters: a Multicenter Retrospective Cohort Study
The goal of this observational study is to learn whether locking peripheral venous catheters with heparin keeps them open (patent) better than locking them with saline, in adults admitted to hospital who have a peripheral venous catheter for intermittent treatment. The main questions it aims to answer are:
- Is the percentage of blocked peripheral venous catheters higher in patients whose catheters are locked with saline than in those whose catheters are locked with heparin?
- Do the rates of other catheter-related complications (phlebitis, catheter-related bloodstream infection, extravasation, and leakage at the insertion site) differ between the two groups?
- Which clinical and drug-related factors are associated with catheter blockage?
Researchers will compare patients admitted to a hospital that routinely locks catheters with saline with patients admitted to a hospital that routinely locks catheters with heparin.
Study Overview
Status
Detailed Description
Maintaining the patency of peripheral venous catheters (PVCs) used intermittently is a relevant and unresolved clinical question. Reference care bundles such as Bacteremia Zero and Phlebitis Zero do not explicitly address whether catheters should be locked with saline or heparin, and the evidence comparing both options, especially taking into account the interval between infusions, is limited.
The two hospitals of the Consorci Sanitari de l'Alt Penedès i Garraf offer a natural experiment: Hospital Residència Sant Camil systematically locks PVCs with sodium heparin 20 IU/mL , while Hospital Comarcal de l'Alt Penedès locks them with sterile 0.9% saline. Allocation to each cohort is determined solely by the hospital of admission. Data for the year before the start of the study will be extracted retrospectively from the electronic medical record, where nurses record the status of the catheter and the reason for removal or replacement on each shift.
The primary analysis will compare, with a superiority approach, the percentage of blocked catheters between cohorts, considering only the first catheter inserted in each patient. Logistic regression will adjust for confounders that are unbalanced between cohorts or clinically relevant (age, sex, type and schedule of intravenous medication, anticoagulation, and coagulation disorders). Sensitivity analyses will include all catheters per patient (mixed models or generalized estimating equations) and will exclude patients at particularly high risk of blockage. Assuming an absolute difference of 3% between cohorts, alpha 5%, power 80%, and 5% losses, 1,725 patients per cohort (3,450 in total) are needed. Data analysts will be blinded to the cohort during the primary analysis.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Noemí Casaponsa
- Phone Number: 43197 0034938960025
- Email: recerca@csapg.cat
Study Locations
-
-
Barcelona
-
Sant Pere de Ribes, Barcelona, Spain, 08810
- Hospital Residència Sant Camil
-
Contact:
- Noemí Casaponsa
- Phone Number: 43197 0034938960025
- Email: recerca@csapg.cat
-
Principal Investigator:
- Esther Moreno Rubio
-
Vilafranca del Penedès, Barcelona, Spain, 08720
- Hospital Comarcal de l'Alt Penedès
-
Contact:
- Noemí Casaponsa
- Phone Number: 43197 0034938960025
- Email: recerca@csapg.cat
-
Principal Investigator:
- Esther Moreno Rubio
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
All adults admitted to Hospital Residència Sant Camil or Hospital Comarcal de l'Alt Penedès (both hospital belonging to CSAPG) during the study period who had at least one peripheral venous catheter inserted for intermittent treatment.
Description
Inclusion Criteria:
- Admitted to Hospital Residència Sant Camil (CSAPG) or Hospital Comarcal de l'Alt Penedès (CSAPG) during the study period
- At least one peripheral venous catheter for intermittent treatment, not inserted in a medical emergency
- Aged 18 years or older
Exclusion Criteria:
- Known allergy to heparin
- Treatment with systemic unfractionated sodium heparin
- Dialysis
- Venous catheter used only for diagnostic tests
- Venous catheter used only for transfusion of blood products
- Participation in another clinical study with drugs or procedures that may affect catheter patency
- Severe heparin-induced thrombocytopenia in recent months
- Uncontrolled active bleeding during admission
- Cerebral aneurysm or dissecting aortic aneurysm, except in association with corrective surgery
- Confirmed or suspected cerebrovascular hemorrhage
- Severe uncontrolled hypertension
- Severe coagulation disorders: platelets below 30,000/µL, prothrombin time ratio above 1.7, or activated partial thromboplastin time ratio above 1.7
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: RETROSPECTIVE
Cohorts and Interventions
Group / Cohort |
|---|
|
Cohort A: saline locking
|
|
Cohort B: heparin locking
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of blocked peripheral venous catheters
Time Frame: Hospital discharge, up to 12 weeks
|
Percentage of patients whose first peripheral venous catheter was removed or replaced because of blockage (occlusion). |
Hospital discharge, up to 12 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSAPG-98
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD (without personal identification data) could be shared by requirement from other researchers after the end of the study, and only for research purposes and previous approval of promotor center of the study (CSAPG). Anyway, Spanish and European Union legal policy about data protection will strictly be followed (IPD will not be transferred outside European Union).
IPD Sharing Time Frame
After publication of main results of the study.
IPD Sharing Access Criteria
IPD will be shared only for scientific research purposes and following the Spanish and European Union normative law about data protection. The requirements will be directed to the IP of the study. The IP will evaluate the request to verify and evaluate the data that is requested and the purposes for which it is requested. Next, the IP will transfer the request to the promotor center the study for the final decision.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.